STAT

Calling embryo editing ‘premature,’ Russian authorities seek to ease fears of a scientist going rogue

The Russian health ministry’s stance puts at least a temporary hurdle in front of Denis Rebrikov's plan to edit the genome of a human embryo.

MOSCOW — Russian health officials are playing down international concerns that a Moscow researcher plans to create gene-edited babies any time soon, saying for the first time that the experiment would be “premature.”

Denis Rebrikov, the scientist who has said he wants to use the genome-editing technology CRISPR to alter embryos, has sparked widespread alarm among scientists who fear that he could become the second researcher to conduct such work, following the birth of gene-edited twins in China last year.

But in a statement issued last week to Russian wire services, the health ministry here said it fully supports the World Health Organization position against making changes to the human germline — the genome of eggs, sperm, and embryos — that would be inherited by future generations “until its implications have been properly considered.” The ministry said it views any clinical use of genome-editing technologies on human embryos “premature.”

The ministry’s stance puts at least a temporary hurdle in front of Rebrikov, who would need the agency’s approval to proceed with his experiment to repair a mutated gene that causes deafness. It’s

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Roche Obesity Drug, An Experimental Lilly Insulin, And More
Roche disclosed that its recently acquired experimental obesity medication helped people lose a significant amount of weight in a Phase 1 trial.
STAT2 min readChemistry
STAT+: Pharmalittle: We’re Reading About Fake Studies, AbbVie Investing In Psychedelics, And More
Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.

Related